FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385702989> ?p ?o ?g. }

• W4385702989 endingPage "e46377e2" @default.
• W4385702989 startingPage "e46377e2" @default.
• W4385702989 abstract "Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Bleeding and thrombotic events are an emerging toxicity associated with chimeric antigen receptor (CAR) T-cell therapies. In lymphoma patients treated with axicabtagene ciloleucel, bleeding occurred in 9% and was associated with low pretreatment platelet count and grade ≥ 3 neurotoxicity (Johnsrud et al Blood Adv. 2022). Aims: The impact of anti-B cell maturation antigen (BCMA) CAR T on hemostasis in patients with relapsed/refractory multiple myeloma (RRMM) has not been reported. Here, we describe the incidence of bleeding and associated factors in RRMM patients receiving anti-BCMA CAR T. Methods: We retrospectively analyzed 83 consecutive RRMM patients with > 30 days follow up after receipt of commercially available anti-BCMA CAR T. Chi-square and Kruskal-Wallis rank sum tests were used to examine differences in baseline patient characteristics and outcomes including overall response rate (ORR), cytokine release syndrome (CRS), and neurotoxicity (NT) by bleeding complications. We did not conduct these analyses by thrombosis due to a small number of events. The ‘cmprsk’ R package was used to estimate cumulative incidence of bleeding and thrombosis events. Results: Eight patients (9.6%) had a bleeding complication and three patients (3.6%) had a thrombotic event. Bleeding occurred at a median of 6.5 days (range, 2-264 days) and thrombosis at a median of 21 days (range,17-109 days). Table 1 demonstrates the study population characteristics by bleeding event. Bleeding sites included gastrointestinal, soft tissue and respiratory tract, while all thrombotic events manifested as deep vein thromboses (Figure 1). Patients who experienced bleeding had a higher disease stage (Revised - International Staging System - 3: 50% vs. 16%, p=0.04), baseline ferritin (935 vs. 260, p=0.04), and peak ferritin post CAR T (7937 vs. 989, p=0.002) compared to patients who did not have a bleeding event. Patients with bleeding were more likely to have a prior history of bleeding compared to those who did not experience bleeding event post CAR T (25% vs. 0%, p=0.008). Both baseline platelet count (58.5 x 103 vs. 150 x 103, p=0.01) and platelet nadir (7 x 103 vs. 49 x 103, p=0.01) were significantly lower among those with versus without bleeding complication, respectively. Baseline coagulation parameters were not significantly different except for slightly higher prothrombin time in those with a bleeding versus no bleeding event (13.8s vs. 11.7s, p=0.03). Prior receipt of anticoagulant was not associated with significant risk of bleeding (25% vs. 16%, p=0.6). Higher grade NT (grade ≥2) was associated with increased risk of bleeding (38% vs. 8%, p=0.03), however, CRS was not. Day 30 ORR was higher among patients who did not experience a bleeding event (73% vs. 38%, p=0.05). However, no difference in response rates were observed at day 90 (67% vs. 38%, p=0.1). Seventy five percent (6/8) of patients required platelet transfusions and 12% (1/8) required fresh frozen plasma during bleeding events. Three of these patients had WHO grade 4 bleeding requiring admission to an intensive care unit. Summary/Conclusion: Patients with more aggressive disease features including higher R-ISS, baseline thrombocytopenia, and grade ≥ 2 NT are at increased risk of bleeding, particularly in the first month post CAR T. Further investigation in a larger cohort is needed to assess risk factors for systemic coagulopathies in patients receiving anti-BCMA CAR T including association with NT and efficacy.Keywords: CAR-T, Bleeding, Multiple myeloma" @default.
• W4385702989 created "2023-08-10" @default.
• W4385702989 creator A5003005994 @default.
• W4385702989 creator A5004190194 @default.
• W4385702989 creator A5004321777 @default.
• W4385702989 creator A5005127427 @default.
• W4385702989 creator A5009719497 @default.
• W4385702989 creator A5012952572 @default.
• W4385702989 creator A5015387189 @default.
• W4385702989 creator A5015707456 @default.
• W4385702989 creator A5015783013 @default.
• W4385702989 creator A5016470756 @default.
• W4385702989 creator A5016931112 @default.
• W4385702989 creator A5017961539 @default.
• W4385702989 creator A5021394406 @default.
• W4385702989 creator A5031358223 @default.
• W4385702989 creator A5035861153 @default.
• W4385702989 creator A5047518602 @default.
• W4385702989 creator A5047819225 @default.
• W4385702989 creator A5049496887 @default.
• W4385702989 creator A5055261814 @default.
• W4385702989 creator A5062342454 @default.
• W4385702989 creator A5062691289 @default.
• W4385702989 creator A5077110117 @default.
• W4385702989 creator A5081601392 @default.
• W4385702989 creator A5082565225 @default.
• W4385702989 creator A5087190330 @default.
• W4385702989 creator A5087799564 @default.
• W4385702989 creator A5091150651 @default.
• W4385702989 creator A5091688355 @default.
• W4385702989 date "2023-08-01" @default.
• W4385702989 modified "2023-09-27" @default.
• W4385702989 title "PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA" @default.
• W4385702989 doi "https://doi.org/10.1097/01.hs9.0000975160.46377.e2" @default.
• W4385702989 hasPublicationYear "2023" @default.
• W4385702989 type Work @default.
• W4385702989 citedByCount "0" @default.
• W4385702989 crossrefType "journal-article" @default.
• W4385702989 hasAuthorship W4385702989A5003005994 @default.
• W4385702989 hasAuthorship W4385702989A5004190194 @default.
• W4385702989 hasAuthorship W4385702989A5004321777 @default.
• W4385702989 hasAuthorship W4385702989A5005127427 @default.
• W4385702989 hasAuthorship W4385702989A5009719497 @default.
• W4385702989 hasAuthorship W4385702989A5012952572 @default.
• W4385702989 hasAuthorship W4385702989A5015387189 @default.
• W4385702989 hasAuthorship W4385702989A5015707456 @default.
• W4385702989 hasAuthorship W4385702989A5015783013 @default.
• W4385702989 hasAuthorship W4385702989A5016470756 @default.
• W4385702989 hasAuthorship W4385702989A5016931112 @default.
• W4385702989 hasAuthorship W4385702989A5017961539 @default.
• W4385702989 hasAuthorship W4385702989A5021394406 @default.
• W4385702989 hasAuthorship W4385702989A5031358223 @default.
• W4385702989 hasAuthorship W4385702989A5035861153 @default.
• W4385702989 hasAuthorship W4385702989A5047518602 @default.
• W4385702989 hasAuthorship W4385702989A5047819225 @default.
• W4385702989 hasAuthorship W4385702989A5049496887 @default.
• W4385702989 hasAuthorship W4385702989A5055261814 @default.
• W4385702989 hasAuthorship W4385702989A5062342454 @default.
• W4385702989 hasAuthorship W4385702989A5062691289 @default.
• W4385702989 hasAuthorship W4385702989A5077110117 @default.
• W4385702989 hasAuthorship W4385702989A5081601392 @default.
• W4385702989 hasAuthorship W4385702989A5082565225 @default.
• W4385702989 hasAuthorship W4385702989A5087190330 @default.
• W4385702989 hasAuthorship W4385702989A5087799564 @default.
• W4385702989 hasAuthorship W4385702989A5091150651 @default.
• W4385702989 hasAuthorship W4385702989A5091688355 @default.
• W4385702989 hasBestOaLocation W43857029891 @default.
• W4385702989 hasConcept C121608353 @default.
• W4385702989 hasConcept C126322002 @default.
• W4385702989 hasConcept C203014093 @default.
• W4385702989 hasConcept C2776364478 @default.
• W4385702989 hasConcept C2777701055 @default.
• W4385702989 hasConcept C2780850621 @default.
• W4385702989 hasConcept C2908647359 @default.
• W4385702989 hasConcept C3875195 @default.
• W4385702989 hasConcept C71924100 @default.
• W4385702989 hasConcept C90924648 @default.
• W4385702989 hasConcept C99454951 @default.
• W4385702989 hasConceptScore W4385702989C121608353 @default.
• W4385702989 hasConceptScore W4385702989C126322002 @default.
• W4385702989 hasConceptScore W4385702989C203014093 @default.
• W4385702989 hasConceptScore W4385702989C2776364478 @default.
• W4385702989 hasConceptScore W4385702989C2777701055 @default.
• W4385702989 hasConceptScore W4385702989C2780850621 @default.
• W4385702989 hasConceptScore W4385702989C2908647359 @default.
• W4385702989 hasConceptScore W4385702989C3875195 @default.
• W4385702989 hasConceptScore W4385702989C71924100 @default.
• W4385702989 hasConceptScore W4385702989C90924648 @default.
• W4385702989 hasConceptScore W4385702989C99454951 @default.
• W4385702989 hasIssue "S3" @default.
• W4385702989 hasLocation W43857029891 @default.
• W4385702989 hasLocation W43857029892 @default.
• W4385702989 hasOpenAccess W4385702989 @default.
• W4385702989 hasPrimaryLocation W43857029891 @default.
• W4385702989 hasRelatedWork W2435227317 @default.
• W4385702989 hasRelatedWork W2916176185 @default.
• W4385702989 hasRelatedWork W2917403768 @default.
• W4385702989 hasRelatedWork W2936186479 @default.

• next